Edition:
United Kingdom

BioLine RX Ltd (BLRX.OQ)

BLRX.OQ on NASDAQ Stock Exchange Capital Market

1.01USD
16 Feb 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.01
Open
$1.03
Day's High
$1.03
Day's Low
$1.01
Volume
19,747
Avg. Vol
71,750
52-wk High
$1.38
52-wk Low
$0.80

Chart for

About

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in... (more)

Overall

No Ratios Available.

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.64
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Biolinerx Announces Partial Monotherapy Results From Phase 2A Combat Study In Pancreatic Cancer

* BIOLINERX ANNOUNCES PARTIAL MONOTHERAPY RESULTS FROM PHASE 2A COMBAT STUDY IN PANCREATIC CANCER

17 Jan 2018

BRIEF-Bioline Rx Ltd Files For Mixed Shelf Of Up To $150 Million

* BIOLINE RX LTD FILES FOR MIXED SHELF OF UP TO $150 MILLION - SEC FILING Source text (http://bit.ly/2lcDvcH) Further company coverage:

28 Dec 2017

InVivo to open crop input unit to outside investors

PARIS, Dec 19 French agricultural group InVivo said on Tuesday that it plans to raise 50 million euros ($59 million) for its Bioline division, which develops crop inputs such as seeds and pesticides, by bringing in outside investors.

19 Dec 2017

BRIEF-BioLineRx Reports Overall Survival Results From Long-term Follow-up of Phase 2a Trial in r/r AML

* BIOLINERX REPORTS OVERALL SURVIVAL RESULTS FROM LONG-TERM FOLLOW-UP OF PHASE 2A TRIAL IN R/R AML

04 Dec 2017

BRIEF-BioLine Rx Ltd Q3 ‍loss per ordinary share $0.07​

* BioLine Rx ltd - qtrly ‍loss per ordinary share $0.07​ Source text for Eikon: Further company coverage:

21 Nov 2017

BRIEF-BioLineRX initiates phase 1b/2 trial for BL-8040 in gastric cancer under immunotherapy collaboration

* BioLineRX announces initiation of phase 1b/2 trial for BL-8040 in gastric cancer under immunotherapy collaboration

18 Oct 2017

BRIEF-BioLineRx announces initiation of Phase 1b/2 trial for BL-8040 in AML under immunotherapy collaboration

* BioLineRx announces initiation of Phase 1b/2 trial for BL-8040 in AML under immunotherapy collaboration Source text for Eikon: Further company coverage:

26 Sep 2017

BRIEF-Biolinerx announces regulatory submission of phase 3 registrational study for BL-8040 in stem cell mobilization

* Biolinerx announces regulatory submission of phase 3 registrational study for bl-8040 in stem cell mobilization

21 Aug 2017

Earnings vs. Estimates